Comparative Pharmacology
Head-to-head clinical analysis: CEFTRIAXONE IN PLASTIC CONTAINER versus DURICEF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFTRIAXONE IN PLASTIC CONTAINER versus DURICEF.
CEFTRIAXONE IN PLASTIC CONTAINER vs DURICEF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ceftriaxone inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking, leading to cell lysis mediated by autolytic enzymes. It has broad-spectrum activity against gram-positive and gram-negative bacteria.
Cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
1-2 g intravenously or intramuscularly every 12-24 hours, maximum 4 g daily.
500 mg to 1 g orally once or twice daily.
None Documented
None Documented
5.8-8.7 hours in adults; prolonged in neonates (18-25 h), elderly, and renal impairment.
1.5-2 hours (prolonged to 20-30 hours in severe renal impairment; dosing adjustment required for CrCl <50 mL/min).
Renal (33-67% as unchanged drug), biliary/fecal (24-44% as active drug and metabolites).
Primarily renal (80-90% unchanged via glomerular filtration and tubular secretion); <10% biliary/fecal.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic